| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910849 | Lung Cancer | 2015 | 5 Pages |
Abstract
Erlotinib appears to be a useful second-line option in PS0/1 patients with EGFR mutation-negative advanced non-squamous NSCLC given its mild adverse effects. The results should be carefully interpreted because of the small sample size, limited power, and retrospective nature of the study.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Akihiro Nishiyama, Nobuyuki Katakami, Hiroshige Yoshioka, Masahiro Iwasaku, Yohei Korogi, Akito Hata, Jumpei Takeshita, Kojiro Otsuka, Kazumi Nishino, Junji Uchida, Takako Okuyama, Yoshinobu Namba, Masahide Mori, Shiro Fujita, Satoshi Morita,